Does a short course of etanercept influence disease progression and radiographic changes in patients suspected of non-radiographic axial spondyloarthritis? Three -years follow- up of a placebo-controlled trial.
Tamara RusmanMac van der WeijdenMichael T NurmohamedC J van DenderenRobert B M LandewePierre M BetCma van der BijlConny J van der LakenIrene E van der Horst-BruinsmaPublished in: Scandinavian journal of rheumatology (2022)
A short course of etanercept in patients with suspected nr-axSpA did not affect disease activity, the chance of biological treatment, or radiographic progression after 3 years of follow-up.
Keyphrases
- disease activity
- ankylosing spondylitis
- rheumatoid arthritis
- rheumatoid arthritis patients
- juvenile idiopathic arthritis
- systemic lupus erythematosus
- end stage renal disease
- ejection fraction
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- pulmonary embolism
- randomized controlled trial
- clinical trial
- patient reported